On January 3, 2024 Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, reported that it will host a call detailing top-line data from its pivotal trial of iopofosine I 131 in Waldenstrom’s macroglobulinemia on Monday, January 8, 2024 at 8:00 am ET (Press release, Cellectar Biosciences, JAN 3, 2024, View Source [SID1234638905]). The company will also be presenting at the Biotech Showcase conference the following day. Details for each event are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Top-line Conference call details:
Date: Monday, January 8, 2024
Time: 8:00 am ET / 5:00 am PT
Dial-in: 1-888-886-7786
Webcast Link: Click HERE

Biotech Showcase Presentation
Date: Tuesday, January 9, 2024
Time: 5:00 pm ET / 2:00 pm PT
Location: Hilton San Francisco Union Square
Webcast: Click HERE
A replay of both the conference call and Biotech Showcase presentation will be available on the investor’s portion of the company’s website.